ASCO: Gilead bolsters Trodelvy in triple-negative breast cancer with practice-changing Keytruda combo win
Already boasting a strong foothold in metastatic triple-negative breast cancer, Gilead Sciences’ Trodelvy has produced positive data that could make the antibody-drug conjugate part of a new front-line standard of care.
Already boasting a strong foothold in metastatic triple-negative breast cancer, Gilead Sciences’ Trodelvy has produced positive data that could make the antibody-drug conjugate part of a new front-line standard of care.
